Navigation Links
ICON and MedAvante Sign Alliance Agreement
Date:3/16/2009

Partnership Aims To Enhance Precision and Reduce High Failure Rates in Central Nervous System Clinical Trials

DUBLIN and Hamilton, N.J., March 16 /PRNewswire-FirstCall/ -- ICON (Nasdaq: ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries and MedAvante, Inc. the leader in centralized psychiatric patient evaluation, today announced that they have signed an alliance agreement. This agreement will couple ICON's global reach and proven excellence in clinical trial management with MedAvante's innovative platform to centralize and calibrate the assessment of patients undergoing treatment in clinical trials. As a result, pharmaceutical and biotechnology trial sponsors will be able to reliably and precisely measure patients' response to therapies.

"MedAvante has developed a platform that addresses a major cause of clinical trial failure in Central Nervous System (CNS) development: variability in both clinical diagnosis of the disorder being studied and ongoing assessment of the severity of the patient's symptoms in a consistent and standardized fashion," says Dr. John Hubbard, President, ICON Clinical Research. "ICON is constantly striving to offer our pharmaceutical and biotechnology partners innovative clinical trial solutions to enhance the drug development process."

"ICON is a proven leader in the provision of high quality clinical research services," says Paul Gilbert, Chief Executive Officer of MedAvante. "This alliance extends our ability to offer our services across the industry and across the globe. Most importantly, however, is what this alliance provides to CNS drug developers: The ability on a larger scale to reduce the high rate of failed CNS clinical trials which the industry recognizes as unacceptable in terms of cost and lost time."

About ICON

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs that support clinical development -- from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 71 locations in 38 countries and has approximately 7,000 employees. Further information is available at www.iconplc.com.

About MedAvante

MedAvante is a global provider of centralized expert psychological rating services to the pharmaceutical, biotechnology, and medical device industries. MedAvante is a pioneer in developing a solution for one of the most intractable problems in CNS clinical trials: the high rate of uninformative or failed studies. MedAvante applies unique methods to systematically remove potential sources of bias and variability from the assessment process. By centralizing assessments with expert, standardized, objective, clinical interviewers over MedAvante's 2-way, real-time, high quality video-conferencing, MedAvante makes subjective assessments of drug efficacy increasingly objective. As a result, sponsors can achieve increased study power and reduced trial-failure rates, enabling them to bring more effective CNS drugs to market sooner. MedAvante operates facilities in Hamilton, NJ; Los Angeles, CA; and Madison, WI. For more information about MedAvante, visit www.medavante.net.


'/>"/>
SOURCE ICON
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
2. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
3. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
4. Lung Cancer Alliance Hails Announcement of New Erbitux(R) Data
5. Lung Cancer Alliance Commends NCCN on Screening Guidelines
6. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
7. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
8. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
9. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
10. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
11. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , January 18, 2017 , , Marks E-QURE ... rd distribution agreement, following similar agreements in ... Wound care is $2 5 ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the ... Tech - Médica Equipos Médicos S.A.S. (TeckMedica) in Colombia ...
(Date:1/19/2017)... Jan. 18, 2017  Magnetic Insight Inc., leader ... into an agreement with inviCRO LLC to develop ... imaging system based on inviCRO,s VivoQuant™ visualization and ... as a complete MPI solution package with the ... or cell imaging in vivo. MPI ...
(Date:1/19/2017)... 2017 The Academy of Managed Care ... (FDA) for its release today of draft guidance ... makers can proactively share clinical and economic information ... emerging therapies awaiting FDA approval. ... AMCP developed during two multi-stakeholder meetings last year ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Ultimate Medical Academy ... who are passionate about making a difference in the lives of the next ... UMA, a nonprofit healthcare educational institution, has more than 30,000 alumni and employs ...
(Date:1/19/2017)... Ashland, VA (PRWEB) , ... January 19, 2017 , ... ... planning services to the eastern Virginia region, is inaugurating a charity event to honor ... community. , While on duty last year, Chad Phillip Dermyer and his fellow officers ...
(Date:1/19/2017)... ... 19, 2017 , ... Creative messages to prevent distracted driving ... Impact Teen Drivers and California Casualty. Entries from students aged 14-22 can be ... $15,000 will be awarded for the best peer-to-peer messages sharing solutions to reckless ...
(Date:1/19/2017)... ... January 19, 2017 , ... Connecticut Dermatology Group (CDG) is proud and ... and compassionate dermatologist. Dr. Kim brings an extensive background in cutting-edge dermatology care ... considerable pleasure to welcome back Dr. Kim to the CDG team” said President and ...
(Date:1/19/2017)... ... , ... Infinity® Massage Chairs announced today that Dan Grover has joined the ... Grover comes with a total of 15 years experience in consumer goods and an ... President of Direct Sales at Traeger® Wood Pellet Grills. , Grover has elevated ...
Breaking Medicine News(10 mins):